Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute. I am so excited to have here with me today, Dr. Kara Maxwell, who is a Cancer Geneticist at the University of Pennsylvania. She also does some work in the VA system there. We are so thrilled […]
Consider this the first of a series of messages on the mission and strategy of the Prostate Cancer Foundation (PCF). The mission of PCF is to reduce the death and suffering from prostate cancer. I often wonder about what would be a good analogy for the mission. As one travels through the world of medical […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute. I’m so excited to have here with me today, Dr. Kara Maxwell, who is a Cancer Geneticist and a Medical Oncologist at the University of Pennsylvania, and also does work at the Penn VA. Thank you so […]
I’m continuing this series focused on metastatic castration-sensitive prostate cancer (mCSPC), as it is a disease state with many upcoming potential changes to standard of care. A couple of months ago, I briefly summarized what is known about the PEACE-1 trial, and I highlighted ongoing chemohormonal therapy trials.1 Since then, there has been a press […]
The CARD study results were reported at the 2019 ESMO meeting and simultaneously published in the NEJM. CARD investigated the efficacy and safety of cabazitaxel as compared with an androgen-receptor-signaling inhibitor ( ARSI; abiraterone or enzalutamide), in patients with mCRPC who were previously treated with docetaxel and had progressed within 12 months while receiving the […]
Testicular cancer severely affects male health, so finding effective diagnosis and prognostic indicators and exploring its pathogenesis are very important. This study aims to explore the hub genes that play important roles in the occurrence and development of testicular germ cell tumor (TGCT).
IRIS™ provides interactive, 3D anatomical visualizations of renal anatomy for pre-operative planning that can be manipulated by altering transparency, rotating, zooming, panning, and overlaying the CT scan.
The tumor immune microenvironment (TIME) and N6-methyladenosine (m6A) are related to the progression of several types of cancer. Nevertheless, the impact of m6A on the TIME of clear cell renal cell carcinoma (ccRCC) remains unclear.
While several recent studies investigated the influence of statins on survival outcomes in prostate cancer (PCa) patients on androgen deprivation therapy (ADT), definitive conclusions are still missing.
Men with unfavorable intermediate-risk (UIR-PCa) or high-risk prostate cancer (HR-PCa) are often treated with definitive external beam radiotherapy (EBRT) plus androgen deprivation therapy (ADT). Treatment is frequently intensified by electively treating the pelvic lymph nodes (LN) with whole pelvis radiotherapy (WPRT), but practice patterns and the benefits of WPRT are not well defined.
